The effect of high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients. A randomized placebo controlled trial

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Mohamed A.A.; Halim A.A.; Mohamed S.; Mahmoud S.M.; Bahgat Eldemiry E.M.; Mohamed R.S.; Shaheen M.M.; Naguib G.G.; Muharram N.M.; Khalil M.G.; Saed S.; Ibrahim R.; Salah Seif A.; Kamal N.; Nasraldin K.; Abdelrahman A.E.; El Borolossy R.

Journal: Frontiers in Pharmacology

Publisher: Frontiers Media S.A.

Publication Date: 14 March 2023

Volume / Issue: Volume 14

Article No.: 1149967

ISSN: 16639812

DOI: 10.3389/fphar.2023.1149967

Scopus: View on Scopus

Document Type: Article

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Mohamed A.A., Department of Biochemistry and Molecular Biology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; Halim A.A., Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; Mohamed S., Tropical Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; Mahmoud S.M., Tropical Medicine Department, El Sahel Teaching Hospital, Cairo, Egypt; Bahgat Eldemiry E.M., Fellow of Clinical Pharmacology, Faculty of Pharmacy, Cairo University Hospitals, Cairo, Egypt; Mohamed R.S., Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Shaheen M.M., Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Naguib G.G., Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Muharram N.M., Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Menoufia, Egypt; Khalil M.G., Pharmacology and Toxicology Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt; Saed S., Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Ibrahim R., Clinical and Chemical Pathology Department, Nutrition Institute, Cairo, Egypt; Salah Seif A., Tropical Medicine Hepatology and Gastroenterology Department, Shebeen El-Kom Teaching Hospital, Menoufia, Egypt; Kamal N., Clinical Pathology Department, Theodor Bilharz Research Institute (TBRI), Ministry of Scientific Research and Higher Education, Gulf Medical University (GMU), Cairo, Egypt; Nasraldin K., Faculty of Biotechnology, Modern Science and Arts University, Cairo, Egypt; Abdelrahman A.E., Diagnostic and Intervention Radiology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; El Borolossy R., Department of Clinical Pharmacy, Faculty of Pharmacy Ain Shams University, Cairo, Egypt


Abstract

Background and Aim: Non-alcoholic fatty liver (NAFLD) is one of the most common progressive metabolic disorders worldwide. There are increasing scientific interests nowadays for the association between vitamin D status and Non-alcoholic fatty liver. Earlier studies have revealed that vitamin D deficiency is highly prevalent in Non-alcoholic fatty liver patients that contributes to poor outcomes. Hence, the present study aimed to assess the efficacy and safety of oral cholecalciferol on Non-alcoholic fatty liver patients. Subjects and Methods: This study was conducted on 140 patients that were randomized either to group 1 that received the standard conventional therapy in addition to placebo or group 2 that received the standard conventional therapy in addition to cholecalciferol during the 4 months study period. Results: At the end of the study group 2 revealed significant decrease (p < 0.05) in the mean serum level of TG, LDL-C, TC, hsCRP as compared to their baseline results and group 1 results. Additionally, a significant improvement in the serum levels of ALT (p = 0.001) was seen in group 2 at the end of the study when compared to group 1. Whereas group 1 did not show any change in these parameters when compared to group 2 and their baseline results. Conclusion: Cholecalciferol was shown to have beneficial effects on serum ALT levels, hsCRP levels and lipid profile of NAFLD patients. Clinical Trial Registration: https://prsinfo.clinicaltrials.gov/prs-users-guide.html, identifier NCT05613192. Copyright © 2023 Mohamed, Halim, Mohamed, Mahmoud, Bahgat Eldemiry, Mohamed, Shaheen, Naguib, Muharram, Khalil, Saed, Ibrahim, Salah Seif, Kamal, Nasraldin, Abdelrahman and El Borolossy.


Keywords

Cholecalciferol; hsCRP; lipid profile; non-alcoholic fatty liver; Steatosis; alanine aminotransferase; C reactive protein; cholesterol; colecalciferol; low density lipoprotein; placebo; triacylglycerol; adult; alanine aminotransferase level; Article; controlled study; drug efficacy; drug safety; echography; female; glycemic control; human; insulin resistance; lipid fingerprinting; loading drug dose; low density lipoprotein cholesterol level; major clinical study; male; metabolic fingerprinting; nonalcoholic fatty liver; protein expression level; randomized controlled trial; single drug dose; total cholesterol level; triacylglycerol blood level


Citation Information

Scopus Citations: 7


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer